

FSA Speaker Series Session 2: Karan Gera from ImmunoAct

About Karan Gera

Karan Gera is a seasoned professional in the biotechnology industry, part of the senior management at ImmunoACT. He manages strategic collaborations to broaden access to lifesaving, genetically modified cellular therapies for specific blood cancers. With a research background in molecular, cellular, and developmental biology of rare metabolic diseases, Karan is a trained biotech engineer.

About ImmunoACT

ImmunoACT is a pioneering biotech company that introduced India's first CAR-T Cell Therapy. They revolutionize cancer treatment with innovative, genetically modified cellular therapies targeting specific blood cancers. ImmunoACT enhances patient outcomes and improves treatment options.

Karan Gera's Engaging Session at my school

Karan Gera conducted an enlightening session on CAR-T Cell Therapy and cancer research for students from classes 8-12. The 1-hour interactive talk sparked curiosity and enthusiasm among the young minds.

During the Q&A session, students actively engaged with Karan, asking thoughtful questions. "What is CAR-T Cell Therapy?" asked one student, prompting Karan to explain the innovative treatment's basics. Another student inquired, "How does it help cancer patients?" Karan shared inspiring success stories, highlighting ImmunoACT's impact on patients' lives. When asked, "Is cancer curable?" Karan discussed various treatment options and the importance of ongoing research.

Students also explored prevention strategies, asking, "Can we prevent cancer?" Karan emphasized the role of healthy lifestyles, regular check-ups, and awareness. One curious student asked, "What inspired you to work in cancer research?" Karan shared his personal experiences and passion for making a difference. The session concluded with students eager to contribute, asking, "How can we contribute to cancer research?" Karan encouraged them to pursue STEM fields, collaborate, and innovate.

Through this engaging session, Karan inspired the next generation to explore biotechnology, cancer research, and medical sciences.